Pulsed Field Ablation Versus Conventional Radiofrequency Catheter Ablation for Repeat PVI in Patients With Paroxysmal AF

Subjects who meet all of the following inclusion criteria at screening will be eligible for enrolment: * Patient had 1 previous PVI with either cryoballoon, RF ablation or PFA * Index PVI occurred within \<5 years prior to enrolment * Documented AF recurrence \>30 seconds * Symptomatic AF * Paroxysmal AF * Age \>18 and \<80 years * Willing and capable to provide informed consent * Able and willing to participate in all examinations and follow-up visits and tests associated with this clinical study Subjects who meet ANY of the following exclusion criteria will be excluded from the study: * Persistent AF (by diagnosis of duration \>7 days) * Concomitant/ prior diagnosis for atrial tachycardia (AT) and/or atrial flutter (AFl). Note typical cavotricuspid isthmus dependent flutter is not an exclusion criterium. * Underwent additional ablations outside the pulmonary veins during index AF ablation * AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other reversible/non-cardiac causes * Contraindication to, or unwillingness to use, systematic anticoagulation * Left ventricular ejection fraction (LVEF) \<30% as documented by transthoracic echo (TTE) (within \<3 months prior) * Left atrial volume index \>60 ml/m2 * Clinically significant arrhythmias other than AF * Previous surgery for AF * New York Heart Association (NYHA) Functional Class III or IV * Presence of intramural thrombus, tumour or other abnormality that precludes safe catheter introduction or manipulation * BMI \>35 kg/m2 * Significant or symptomatic hypotension, bradycardia, or chronotropic incompetence * Chronic renal insufficiency of \<15 mL/min/1.73 m2 or any history of renal dialysis, or history of renal transplant * Hemodynamically significant valvular disease * Presence of patent foramen ovale (PFO) or atrial septal defect (ASD) closure device * History of abnormal bleeding and/or clotting disorder * History of rheumatic fever * Severe lung disease, pulmonary hypertension, or any lung disease. Only if involving abnormal blood gases or significant dyspnoea * Clinically significant systemic infection or sepsis * Life expectancy \<1 year * Sensitivity to contrast media not controlled by pre-medication * Any of the following within the 3 months prior to enrolment: * Myocardial infarction * Unstable angina * Percutaneous coronary intervention * Heart failure hospitalization * Stroke or TIA * Significant bleeding * Pericarditis/effusions * Left atrial thrombus * Coronary artery bypass grafting/atriotomy within 6 months prior * Organ or haematologic transplant, or currently being evaluated for an organ transplant * Women who are pregnant or breastfeeding